Avandia (Rosiglitazone): Ongoing Review of Cardiovascular Safety

On February 22, 2010, the U.S. Food and Drug Administration (FDA) issued information about the safety of Avandia (Rosiglitazone). The FDA is currently studying information in light of U.S. Department of Finance investigation that alleges the makers of Avandia may not have advised the FDA, physicians and patients about heart attack risks associated with the diabetes drug.

Avandia patients who have suffered a heart attack or other serious cardiac injuries can obtain more information about their legal options from our attorneys.

Audience: Endocrinology, cardiology healthcare professionals, patients

FDA notified healthcare professional and patients that it is reviewing the primary data from a large, long-term clinical study, RECORD, on possible cardiovascular risks with the diabetes drug, Avandia (rosiglitazone). In addition to the clinical trial, a number of observational studies of the cardiovascular safety of rosiglitazone have been published and FDA has been reviewing these on an ongoing basis.

These reviews are ongoing and no new conclusions or recommendations about the use of rosiglitazone in the treatment of type 2 diabetes have been made at this time. Once FDA completes its review of the data from the RECORD study, the agency will present the totality of new and existing cardiovascular safety data on rosiglitazone at a public meeting in July 2010. The Agency will provide an updated assessment of the risks and benefits of rosiglitazone in the treatment of type 2 diabetes.

FDA recommends that healthcare professionals follow the recommendations in the drug label when prescribing rosiglitazone. This includes a Boxed Warning. Patients should continue taking rosiglitazone unless told by their healthcare professional to stop. Patients who are concerned about the possible risks associated with using rosiglitazone should talk to their healthcare professional.

Get Help from Weitz & Luxenberg
If you or a loved one has suffered a heart attack or other serious cardiac complications after taking Avandia to treat their diabetes, our lawyers may be able to help you seek compensation against the responsible companies for the injury, pain and suffering, and other monetary compensation to defray medical or other expenses.

Please complete the form on this page for a free review of your potential lawsuit. A Weitz & Luxenberg representative will contact you as soon as possible.

Click To Talk To Us Online

FDA Safety Review

FDA review of Avandia (Rosiglitazone) | Weitz & Luxenberg attorneys
Those who suffered a heart attack or other serious heart problem after taking Avandia (Rosiglitazone) can obtain a free lawsuit review from our lawyers

2-10 FDA Communication

FDA advisory regarding Avandia and its generic | Weitz & Luxenberg
News about Avandia and its generic form, Rosiglitazone, which have been linked to heart attack risk. Those affected can get a free lawsuit review.

Name

Phone

strictly confidential

Your Question

Contact Name
Email Address
Phone Number
When did you start taking Avandia?
Did you experience cardiovascular problems after taking Avandia?
What was the date you experienced cardiac complications?
Did you have any cardiovascular disease before taking Avandia?
Did you suffer a bone fracture after taking either Avandia or Actos?
Please provide detail about your bone fracture injury, including the date of the injury, how the fracture occured and what bone(s) were affected.
Additional information